‘Achilles’ Heel’ of the Herpes Virus Possibly Found in Marijuana

“It’s one of the most common viruses in America, and one that causes the most guilt and shame. It can get inside almost any kind of human cell, reproduce in vast numbers, and linger for years in the body, causing everything from recurrent genital blisters to sores around the mouth. Its complications can kill, and it may increase susceptibility to many nerve and brain disorders.

But until now, scientists haven’t fully understood how the herpes simplex virus (HSV) manages to do all of this. And that has stood in the way of developing more targeted, effective treatments against it to help those infected.

New research from the University of Michigan Medical School may help change that.

An estimated 45 million Americans have genital herpes and millions more have the more visible oral variety. Once someone is infected, they’re infected for a lifetime. New medicines for herpes infection are badly needed; currently, antiviral drugs can quell symptoms of an outbreak, but not eliminate the virus. And, there’s increasing evidence that HSV may damage the nerve cells in which it hides between outbreaks, possibly contributing to neurological disease.

In a presentation Sunday at the International Congress of Virology and in two new papers in the Journal of Virology, U-M researchers are reporting the discovery of a receptor that appears to function as one “lock” that HSV opens to allow it to enter human cells. They’ve also found the gene that controls the production of that receptor, deciphered some aspects of the receptor’s structure, and developed a pig-cell system that could be used to test new anti-herpes drugs.

The findings may help explain why the oral and genital herpes virus has such a successful track record: The receptor, dubbed B5, is made by most cells for another purpose not yet understood. HSV appears to have evolved a way to latch onto it, and fool the cell into letting the virus in. And since most cells express the gene for the B5 receptor, this may be a reason HSV can get into most kinds of cells.

“This may be one central part of the Achilles’ heel in interactions of herpes virus with a cell to start infection. We can use the receptor molecule to try to understand the process and perhaps combat infection at this vulnerable site,” says A. Oveta Fuller, Ph.D. the leader of the U-M team, senior author on the two papers and an associate professor in the U-M Medical School’s Microbiology and Immunology Department. “While we’re still a few years away from being able to use this new knowledge to find effective drug candidates, this is a very exciting confluence of discoveries.”

The U-M holds a patent on the system and methods that the team used to make the discoveries.

Coincidentally, the U-M team’s findings about the B5 receptor are being published at about the same time as an Italian team’s reports about a possible ‘key’ on the herpes simplex virus surface that may match the ‘lock’ found by the U-M team. The Italian team has identified a region of a viral surface protein that matches the U-M team’s predictions of what the virus likely would use to bind and engage the B5 receptor.

“It appears that B5 is a new class of viral receptor. Unlike other viruses so far, HSV seems to have evolved to take advantage of a broadly present cellular protein that has properties like that of known cellular fusion machinery,” says Fuller. “No other virus has been shown to use a cellular fusion protein for entry into cells.”

She explains that the search for the mechanisms by which HSV enters cells has been hindered by the fact that the virus is very good at entering so many kinds of cells. The many possibilities for virus binding to cells make deciphering the entry process a difficult problem to solve.

The gene that encodes B5 had in fact been sequenced, but not characterized, as part of the Human Genome Project. Discovering its role and studying the HSV entry mechanism was tricky and near impossible until Fuller’s team discovered a type of pig kidney cell that isn’t vulnerable to infection by human herpes virus. They searched the genome library to find genes essential to HSV infection, isolated the B5-coding sequence, and figured out how to get pig cells to express the human B5 protein to allow the pig cells to be infected with human herpes virus.

For these studies, Fuller credits the persistence of research team members in working with the genomic library and culture of human and pig cells, especially U-M doctorate graduate Aleida Perez and postdoctoral fellows Qingxue Li and Pilar Perez-Romero. Perez-Romero is first author of one of the two new papers, and a co-author on the other.

The two new papers show that the B5 receptor has important features that could explain why it is important to HSV’s ability to fuse with the fluid membrane that encloses every human cell. The researchers were able to show that by placing only the DNA sequence that encodes B5 into HSV-resistant pig cells, they could make the pig cells susceptible to HSV. They were also able to block viral infection of both human cells and susceptible pig cells by adding to cell cultures a synthetic peptide made to mimic the structure of a smaller region of the B5 receptor. This peptide looks like a functional region of B5 and apparently interferes with virus engaging of the cell receptor.

The papers detail how the team isolated and characterized the gene that encodes B5, called hfl-B5, and used the DNA sequence to find out more about the protein structure of the B5 receptor. In the presentation at the International Congress for Virology, Fuller will describe recent findings that further confirm B5’s importance in HSV infection.

The virology team reports that the B5 molecule appears to form a shape called a coiled coil. This intricately wound structure, they believe, may be similar to the structure of some fusion proteins of viruses and also to cellular proteins called SNAREs. Typically, SNARE proteins help cells to manage the fusion of membranes of vesicles inside the cell with other specific vesicles. Vesicles are tiny membrane-encased packets that encapsulate neurotransmitters, enzymes or other important substances and allow them to be transported within and between cells.

The researchers were able to show that B5 sits in the cell membrane with one end of the protein exposed outside of the cell ready to link up with viruses — or to serve the receptor’s “real” function, which still remains to be discovered. They also showed that HSV does not enter into pig cells that have an altered human B5 protein that is changed by mutations that affect a functional region important to forming a coiled coil.

“If B5 is a SNARE-like cell fusion receptor”, Fuller says, “it may turn out to be useful for more than HSV drug treatment. It could act as a way to link vesicles containing drugs with cells, and deliver them inside”. She is currently collaborating with U-M nanotechnology researchers on this concept.

The findings suggest that B5 or its viral ligand could be a target for antiviral treatment, much like cell receptors for the entry of human immunodeficiency virus (HIV) into cells have become targets for new AIDS drugs.”

http://www.hightimes.com/read/achilles-heel-herpes-virus-possibly-found-marijuana

Patent: CA 2771800 A1: Herbal medication for cold sores and genital herpes and preparation thereof

“The present invention generally relates to herbal medications. More particularly, it relates to formulations to treat cold sores and genital herpes. The ingredients of this formulation are cannabis oil and cannabis roots, which are used to treat genital herpes, cold sores and other viral diseases.

SUMMARY OF THE INVENTION

The disclosed formulation comprises cannabis oil and cannabis root fibres. The person with herpes surrounds the lesion with the cannabis oil such that the lesion is completely covered. The root fibres are then applied over the oil-covered lesions.

Finally, medical gauze is applied over the treated areas and secured to the skin. Within 24 hours, the gauze may be removed. The herpes lesions heal and, of significance, outbreaks do not recur.
An individual genital herpes treatment comprises 1 gram of oil and 0.5 gram of root fibres.
CLAIMS
1. A formulation of cannabis oil and cannabis root powder to treat viral diseases, whereby there is no recurrence of the disease after one treatment.”

Compounds in cannabis could limit stroke damage

A cannabis plant

“Chemical compounds found in cannabis may help to reduce brain damage following a stroke, new research has revealed.

 Researchers at the University of Nottingham conducted a meta-analysis of experimental studies into cannabinoids; chemicals related to those found in cannabis, some of which also occur naturally in the body. The findings showed that the compounds could reduce the size of stroke and improve neurological function.
Cannabinoids can be classified into those found naturally in the body (endocannabinoids), those made artificially (synthetic cannabinoids) or those derived from extracts from the plant cannabis sativa (phytocannabinoids).”

Marijuana Use Linked To Lower Stroke Risk

(Photo: comedy_nose/Flickr)

“Those who use marijuana may benefit from a reduced chance of stroke, according to a new study.

As part of The Stroke Prevention in Young Adults Study, researchers from the University of Maryland analyzed past marijuana use among 751 stroke cases and 813 controls.

The results, which spanned 16 years, showed that those who used marijuana were less likely to suffer a stroke. 28.8% of stroke patients reported marijuana use verses 32.7% of those with no history of stroke.

“The question is still out there, the research still needs to be done. Patients are interested, and I think this lays a foundation for that,” said Dr. Billinghurst.

However, cochair Jennifer Majersik, MD, of the University of Utah, said the study “should be reassuring” to people who smoked marijuana in the 1960s or 1970s, adding that Baby Boomers have yet to show any negative marijuana-associated effects.

Factors that seemed to increase the risk of stroke included tobacco and alcohol use and a history of diabetes and hypertension. Stroke sufferers also tended to be male.

‘Extremely Promising’

Other studies have suggested a link between marijuana use and an increased risk of stroke, but opinions remain divided. On the other hand, there is a growing body of evidence that supports a beneficial role of medical marijuana following a stroke.

In 2013, researchers at the University of Nottingham analyzed pre-existing evidence and concluded that marijuana compounds, called cannabinoids, show promise in reducing the severity of stroke and improving patient outcomes.

“The data are guiding the next steps in experimental stroke in order to be able to progress onto initial safety assessments in a clinical trial,” said lead author and stroke specialist Dr. Tim England.

An earlier analysis of cannabinoids in post-stroke treatment, published in 2012, concluded that “both synthetic cannabinoids and endocannabinoids represent extremely promising therapeutic compounds.”

According to the 2012 findings, compounds that bind to the body’s marijuana pathways may offer protection against post-stroke injury due to their “potent anti-inflammatory” effects.”

http://www.leafscience.com/2014/05/13/marijuana-use-linked-lower-stroke-risk/

Stroke survivors could be given cannabis to reduce brain damage

“SCIENTISTS are considering running a trial which would see stroke survivors given the illegal class-B drug cannabis in a bid to reduce brain damage.

The “exciting” research has been compiled by researchers at the University of Nottingham, who have pulled together research from around the world to suggest that ‘cannabinoids’ – chemicals related to those found in cannabis, some of which also occur naturally in the body – could reduce the size of stroke and improve neurological function.

The research – so far which has only been done on rats – indicates that all three classes of cannabinoid could be effective in shrinking the area of the brain affected by stroke and in recovering neurological function.

Dr Tim England honorary consultant stroke physician at the University of Nottingham and Royal Derby Hospital led the study.

He said: “This meta-analysis of pre-clinical stroke studies provides valuable information on the existing, and importantly, missing data on the use of cannabinoids as a potential treatment for stroke patients.”

http://www.nottinghampost.com/Stroke-survivors-given-cannabis-reduce-brain/story-20249666-detail/story.html

 

Researchers Meet to Discuss Cannabinoid-Based Stroke Therapy

Murikinati et al., 2010 shows that brain tissue is saved after a stroke with JWH-133

“The Cannabinoid Discussion Group at Temple University met for the second time this semester to review a recent scientific publication from a German Laboratory. The presenter was Zachary Reichenbach, an MD/Ph.D student at Temple, who is currently working in the laboratory of Dr.Ron Tuma. The Tuma lab is focused on studying cannabinoid based therapies for the treatment of cerebral ischemia resulting from stroke. Mr.Reichenbach led the discussion on a research paper which showed that the cannabinoid JWH-133 activates the cannabinoid type 2 receptor (CB2R), resulting a decrease in infarct size or brain damage duringreperfusion following an ischemic event.

Mr.Reichenbach provided background on stroke, stating that it is the 3rd cause of death in this country, and 85% of those strokes are of the ischemic variety. During an ischemic event there is a hyper-immune response resulting in the recruitment of immune cells that kill brain tissue. Cannabinoids have been shown to modulate the immune system, notably the Tuma lab has published data on the CB2 receptor’s anti-inflammatory effects. Activating the CB2 receptor decreases the migration of hyper-immune cells to the brain. The more brain you save, the more you save someone from disabilities or death.

When asked about the implications of these findings on a cannabinoid that could be a potential stroke therapy, Mr.Reichenbach replied that the results of his work and others is promising…

And just in case you were wondering, THC, the active ingredient in Cannabis, activates both the CB1 and CB2 receptor.”

http://www.examiner.com/article/researchers-meet-to-discuss-cannabinoid-based-stroke-therapy

Cannabis may help stroke recovery

“CANNABIS may help to reduce brain damage after a stroke, new research suggests.

Chemical compounds found in the plant could help shrink the area of the brain affected by stroke, the study says.

Cannabinoids in the plant, as well as those that can be made artificially and those found naturally in the body, can also help improve brain function after a stroke attack, the authors said.

The study, which is to be presented to the annual UK Stroke Forum, examined previous studies conducted on the effect of the compound.

The authors, from the University of Nottingham, examined 94 studies evaluating the effects of cannabinoids on 1022 male rats, mice or monkeys.

They say the chemical “shows promise as a neuroprotective treatment for stroke”.

“This meta-analysis of pre-clinical stroke studies provides valuable information on the existing, and importantly, missing data on the use of cannabinoids as a potential treatment for stroke patients,” said lead author Dr Tim England, honorary consultant stroke physician at the University of Nottingham and Royal Derby Hospital.

Dr Dale Webb, director of research and information at the Stroke Association, added: “Stroke is the leading cause of adult disability in the UK, with more than half of all stroke survivors left dependent on others for everyday activities. With more people in the UK surviving a stroke, it’s never been more important to find new treatments to help more stroke patients make better recoveries.

“This new research is an example of the many new developments in the field of stroke which are being presented at this year’s UK Stroke Forum.

“The findings have identified the potential for cannabinoids to reduce brain damage caused by stroke.”

http://www.news.com.au/world/breaking-news/cannabis-may-help-stroke-recovery/story-e6frfkui-1226774100340

Cannabinoids drug for inflammatory bowel

Medindia

“Researchers from the University of Bath, UK has found that Cannabinoids derived from Cannabis has found to be effective in the treatment of inflammatory bowel diseases like Crohn’s disease and ulcerative colitis.

“The system that responds to cannabis in the brain is present and functioning in the lining of the gut,” lead researcher Dr. Karen Wright, of the University of Bath, explained to Reuters Health. “There is an increased presence of one component of this system during inflammatory bowel diseases,” she explained.

The report of the study was published in the Journal of Gastroenterology in which she has explained the location of CB1 and CB2 receptors in human colon tissue which binds to the Cannabinoid. She has used Human colon cell lines to establish the binding of the cannabinoid compounds and in her wound healing experiments.

Increased CB2 receptors are found in colonic tissue characteristic of inflammatory bowel disease. They found that the Cannabinoids helps in wound healing of the surface by CB1 related receptor mechanism.

“Cannabinoids, which we make ourselves, as well as synthetic Cannabinoids, can promote wound healing in the gut, which is extremely interesting given that inflammatory bowel disease involves damaged gut linings,” Wright said.”

http://www.medindia.net/news/view_news_main.asp?x=4578

Long-term cannabinoid type 2 receptor agonist therapy decreases Bacterial Translocation In Rats with cirrhosis and ascites.

“Intestinal hyper-permeability, impaired peritoneal macrophages (PMs) phagocytosis, and, bacterial translocation (BT) resulting in increased systemic and local infection/inflammation such as spontaneous bacterial peritonitis (SBP), together with increased tumor necrosis factor-α (TNFα) levels, are all implicated in the pathogenesis of cirrhosis-related complications.

Manipulation of cannabinoid receptors (CB1R and CB2R), which are expressed on the gut mucosa and PMs, has been reported to modulate intestinal inflammation and systemic inflammatory cytokines release. Our study aims to explore the effects of chronic CB1R/CB2R agonist/antagonist treatments on relevant abnormalities in cirrhotic ascitic rats…

CONCLUSIONS:

Our study suggests that CB2R agonist have the potential to treat BT and various relevant abnormalities through the inhibition of systemic/intestinal oxidative stress, inflammatory cytokines and TNFα releases in cirrhosis. Overall, chronic CB2R agonist treatment affects multiple approach mechanisms, and the direct effect on hyperdynamic circulation is only minor.”

http://www.ncbi.nlm.nih.gov/pubmed/24953022

Effects of the novel cannabinoid CB1 receptor antagonist PF 514273 on the acquisition and expression of ethanol conditioned place preference.

“The centrally expressed cannabinoid receptor (CB1) has been considered a potential therapeutic target in treating alcoholism.

Though CB1 receptors have been shown to modulate primary and conditioned ethanol reward, much of this research employed animal models that require ethanol ingestion or oral routes of administration. This is problematic considering CB1 antagonist drugs have high anorectic liability and have been used clinically in the treatment of obesity. Therefore, the present study examined CB1 antagonism in DBA/2J mice using an unbiased ethanol-induced conditioned place preference (CPP) procedure, a paradigm that does not require ethanol ingestion…

Results from the present study appear inconsistent with other studies that have demonstrated a role for CB1 antagonism in ethanol reward using oral administration paradigms.

Our findings suggest that CB1 antagonism may have greater involvement in consummatory behavior than ethanol reward.”

http://www.ncbi.nlm.nih.gov/pubmed/24954022

http://www.thctotalhealthcare.com/category/addiction/